Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 28

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 28
---
 information contained in this prospectus and incorporated by reference in this prospectus.

| (£ in thousands)          |     | As of December 31, 2024 |       |     |                        |        |     |             |
|:--------------------------|:----|:------------------------|------:|:----|:-----------------------|-------:|:----|:------------|
|                           |     | Actual (audited)        |       |     | Pro Forma  (unaudited) |        |     | Pro-Forma   
 As-Adjusted 
 (unaudited) 
 (1)(2)      |
| Cash and cash equivalents |     |                         | 1,669 |     |                        |  5,361 |     |             |
| Long-term debt            |     |                         |   118 |     |                        |    118 |     |             |
| Total equity              |     |                         | 8,322 |     |                        | 12,014 |     |             |
| Total capitalization      |     |                         | 8,440 |     |                        | 12,132 |     |             |

_____________

| (1) | A $1.00 increase or decrease in the assumed combined public offering price of $ per Unit, which is the                                         
 last reported sale price of our Depositary Shares on the NASDAQ Capital Market on          , 2025, would increase or decrease, as appropriate, 
 our pro-forma as adjusted cash and cash equivalents, total equity and total capitalization by approximately £        million, assuming         
 the number of units offered by us as set forth on the cover page of this prospectus remains the same, and after deducting the estimated        
 underwriting discounts and commissions and estimated offering expenses payable by us.                                                          |

| (2) | All proceeds from the sale of the units have been reflected within Total equity for purposes of this table.                                 
 We will be required to complete an assessment of the accounting and valuation for such instruments, which may result in a portion of the    
 proceeds being classified outside of Total equity and remeasured to fair value each reporting period (if liability-classified instruments). 
 Such assessment will be completed in connection with the preparation of our consolidated financial statements for the period in which       
 the sales occur.                                                                                                                            |

The number of our Ordinary Shares to be outstanding
immediately after this offering is calculated based upon 6,685,918,822 Ordinary Shares outstanding as of December 31